Opthea Limited Investor Relations Material
Latest events
Investor Day
Opthea Limited
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Opthea Limited
Access all reports
Opthea Limited is a clinical-stage biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative therapies primarily for eye diseases. The company's primary focus is on advancing its intellectual property portfolio, which encompasses Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3. These are aimed to be used in treating diseases associated with blood and lymphatic vessel growth as well as vascular leakage. The company is headquartered in South Yarra, Victoria, Australia, and its shares are listed on the NASDAQ and ASX.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
OPT
Country
🇦🇺 Australia